Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Methylation of eNOS in the rat penile corpus cavernosum under different pathological states and its relationship with erectile function

Methylation of eNOS in the rat penile corpus cavernosum under different pathological states and... INTRODUCTIONErectile dysfunction (ED) refers to the absence of the ability to achieve or sustain an erection and achieve satisfactory sexuality.1 More than 150 million men worldwide are reported to have ED. The number of ED patients might exceed 320 million by 2025.2 Aging, diabetes, and cardiovascular disease are common causes of ED.3 Phosphodiesterase type 5 inhibitors (PDE5Is) are used to treat ED as first‐line drugs. However, PDE5Is are ineffective in approximately 35% of ED patients.4 The effectiveness of ED treatment may be greatly improved by using different treatment protocols according to different etiologies.DNA methylation is a form of chemical modification of DNA that can affect gene expression without altering the DNA sequence through the action of DNA methyltransferases. The methyltransferase family includes DNMT1, DNMT3a, and DNMT3b.5,6 DNMT1 plays a vital role in maintaining DNA methylation, and knockout of DNMT1 causes two‐thirds of DNA methylation to be lost in embryos, which is accompanied by a large amount of cell apoptosis, indicating that DNMT1 plays a critical role in cell differentiation and development. DNMT3a and DNMT3b are new methyltransferases that transfer methyl groups to unmethylated DNA sequences. Knockdown of DNMT3a and DNMT3b revealed that normal cell differentiation requires DNMT3a and that http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Andrology Wiley

Methylation of eNOS in the rat penile corpus cavernosum under different pathological states and its relationship with erectile function

Loading next page...
 
/lp/wiley/methylation-of-enos-in-the-rat-penile-corpus-cavernosum-under-71fqujfP9P

References (34)

Publisher
Wiley
Copyright
© 2024 American Society of Andrology and European Academy of Andrology.
ISSN
2047-2919
eISSN
2047-2927
DOI
10.1111/andr.13465
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONErectile dysfunction (ED) refers to the absence of the ability to achieve or sustain an erection and achieve satisfactory sexuality.1 More than 150 million men worldwide are reported to have ED. The number of ED patients might exceed 320 million by 2025.2 Aging, diabetes, and cardiovascular disease are common causes of ED.3 Phosphodiesterase type 5 inhibitors (PDE5Is) are used to treat ED as first‐line drugs. However, PDE5Is are ineffective in approximately 35% of ED patients.4 The effectiveness of ED treatment may be greatly improved by using different treatment protocols according to different etiologies.DNA methylation is a form of chemical modification of DNA that can affect gene expression without altering the DNA sequence through the action of DNA methyltransferases. The methyltransferase family includes DNMT1, DNMT3a, and DNMT3b.5,6 DNMT1 plays a vital role in maintaining DNA methylation, and knockout of DNMT1 causes two‐thirds of DNA methylation to be lost in embryos, which is accompanied by a large amount of cell apoptosis, indicating that DNMT1 plays a critical role in cell differentiation and development. DNMT3a and DNMT3b are new methyltransferases that transfer methyl groups to unmethylated DNA sequences. Knockdown of DNMT3a and DNMT3b revealed that normal cell differentiation requires DNMT3a and that

Journal

AndrologyWiley

Published: Jan 1, 2024

Keywords: androgen; diabetes; eNOS; erectile function; methylation

There are no references for this article.